Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use
EMJ Oncology · 2022
DOI: 10.33590/emjoncol/10128767 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMJ Oncology, 2022. Verfasst von Katherine Colvin.
Abstract (Originalsprache)
EXPLORING the current state of use of immunotherapies in the treatment of non-small cell lung cancer (NSCLC) and looking to future immunotherapeutic pathways, three expert speakers presented a session at European Society for Medical Oncology (ESMO) Congress 2022, on the 12 th of September.The speakers shared insights on personalising current uses of immunotherapeutics in NSCLC, the use of immunotherapies in patient populations traditionally excluded from clinical trials, and the immune pathways and strategies that could be utilised in future immunotherapeutic management of lung cancer.
Zitieren
APA
Colvin, K. (2022). Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use. EMJ Oncology. https://doi.org/10.33590/emjoncol/10128767
Vancouver
Colvin K. Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use. EMJ Oncology. 2022. doi:10.33590/emjoncol/10128767
BibTeX
@article{Colvin2022,
author = {Colvin, Katherine},
title = {Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use},
journal = {EMJ Oncology},
year = {2022},
doi = {10.33590/emjoncol/10128767}
}
EUVIMED